Search: (L773:2055 6845) pers:(Koul Sasha) >
Relationship betwee...
-
Sharma, TaniaLund Univ, Clin Sci, Dept Cardiol, Lund, Sweden,Lund University
(author)
Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction : a VALIDATE-SWEDEHEART substudy
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2019-05-15
-
OXFORD UNIV PRESS,2020
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-409663
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409663URI
-
https://doi.org/10.1093/ehjcvp/pvz015DOI
-
https://lup.lub.lu.se/record/1b3addc2-4a1f-47f3-80b0-a662e75fc9a2URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:143312729URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Aims: Heparin is the preferred choice of anticoagulant in percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). An established dosage of heparin has not yet been determined, but treatment may be optimized through monitoring of activated clotting time (ACT). The aim of this study was to determine the relationship between heparin dose or ACT with a composite outcome of death, MI, or bleeding using data from the registry-based, randomized, controlled, and open-label VALIDATE-SWEDEHEART trial, although patients were not randomized to heparin dose in this substudy.Methods and results: Patients with MI undergoing PCI and receiving treatment with a potent P2Y12-inhibitor and anticoagulation with heparin, without the planned use of glycoprotein IIb/IIIa inhibitor (GPI), were enrolled in this substudy. The primary endpoint was a composite endpoint of death, MI, and bleeding at 30 days. The individual components and stent thrombosis were analysed separately. We divided patients into groups according to the initial dose of unfractionated heparin during PCI (<70 U/kg, 70-100 U/kg, and >100 U/kg) or ACT (ACT <250 s, 250-350 s, and >350 s) as well as investigating them as continuous variables in Cox proportional hazards models using univariable and multi-variable analyses. No major differences were noted between heparin stratified in groups (P = 0.22) or heparin as a continuous variable in relation to the primary composite endpoint hazard ratio (HR) 1.0 confidence interval (CI) (0.99-1.01) for heparin dose/kg. No differences were found between ACT stratified in groups (P = 0.453) or ACT in seconds HR 1.0 CI (0.99-1.00) regarding the primary endpoint. The individual components of death, MI, major bleeding, and stent thrombosis were not significantly different across heparin doses or ACT levels either.Conclusion: We found no association between heparin dose or ACT levels and death, MI bleeding complications, or stent thrombosis. Therefore, there is no strong support for a specific heparin dose or mandatory ACT monitoring in patients treated with potent P2Y12-inhibitors with no planned GPI.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Rylance, RebeccaLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)re4842ry
(author)
-
Karlsson, SofiaLund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups(Swepub:lu)so3855ka
(author)
-
Koul, SashaLund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups(Swepub:lu)med-sku
(author)
-
Venetsanos, DimitriosKarolinska Institutet,Danderyd Hospital
(author)
-
Omerovic, ElmirSahlgrens Acad, Dept Cardiol, Gothenburg, Sweden,Sahlgrenska Academy
(author)
-
Fröbert, OleÖrebro University
(author)
-
Persson, JonasKarolinska Institutet,Danderyd Hospital
(author)
-
James, Stefan,1964-Uppsala University,Uppsala universitet,Kardiologi(Swepub:uu)stjam367
(author)
-
Erlinge, DavidLund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups(Swepub:lu)kard-der
(author)
-
Lund Univ, Clin Sci, Dept Cardiol, Lund, SwedenLund University
(creator_code:org_t)
Related titles
-
In:European Heart Journal - Cardiovascular Pharmacotherapy: OXFORD UNIV PRESS6:1, s. 6-132055-68372055-6845
Internet link
Find in a library
To the university's database
- By the author/editor
-
Sharma, Tania
-
Rylance, Rebecca
-
Karlsson, Sofia
-
Koul, Sasha
-
Venetsanos, Dimi ...
-
Omerovic, Elmir
-
show more...
-
Fröbert, Ole
-
Persson, Jonas
-
James, Stefan, 1 ...
-
Erlinge, David
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European Heart J ...
- By the university
-
Uppsala University
-
Lund University
-
Karolinska Institutet